Alexion Europe SAS

ALXN1850 (Strensiq) is a recombinant alkaline phosphatase enzyme replacement therapy developed by Alexion Europe SAS for the treatment of hypophosphatasia (HPP), a rare genetic disorder characterized by deficient alkaline phosphatase activity. The active pharmaceutical ingredient is asfotase alfa, administered as a subcutaneous injection available in 40 mg/ml and 100 mg/ml formulations. The program is currently in Phase 3 development, specifically evaluating ALXN1850 versus asfotase alfa in pediatric patients aged 2 to under 12 years with HPP who have prior exposure to asfotase alfa therapy, under the trial designation ALXN1850-HPP-303 (Chestnut study).

Strensiq has already achieved regulatory approval in multiple jurisdictions: approved in the European Union (EMA authorization dated 16 February 2026), Japan (July 2015), and the United States (BLA125513). The Phase 3 trial represents a comparative efficacy and safety evaluation in a pediatric population with prior treatment experience, positioning the program to potentially expand the clinical evidence base for this rare disease indication. Alexion's strategy appears focused on demonstrating therapeutic value in treatment-experienced pediatric patients, a clinically relevant subset within the HPP patient population.

Hypophosphatasia is a rare inherited metabolic disorder with significant unmet medical need. The disease causes deficient alkaline phosphatase activity, leading to impaired bone mineralization, dental abnormalities, muscle weakness, and in severe cases, respiratory compromise and mortality. Pediatric patients represent a particularly vulnerable population, as early-onset HPP can result in severe skeletal deformities and life-threatening complications during critical developmental periods.

The competitive landscape for HPP treatment is limited, with asfotase alfa (Strensiq) representing the primary enzyme replacement therapy option. The Phase 3 Chestnut trial's focus on treatment-experienced pediatric patients addresses a specific clinical population—those who have already initiated asfotase alfa therapy—and seeks to establish comparative safety and efficacy data. This positioning is commercially significant as it may support label expansion, treatment optimization strategies, or demonstrate superiority in defined patient subsets.

The rare disease designation and limited treatment options create a specialized market with high unmet need. Pediatric HPP patients require long-term management, creating sustained revenue potential. Regulatory approvals across major markets (EU, US, Japan) indicate established commercial infrastructure and market access, while the Phase 3 trial may unlock additional clinical evidence supporting expanded use or optimized dosing strategies in the pediatric population.

Drug Class: Recombinant alkaline phosphatase enzyme replacement therapy

Active Ingredient: Asfotase alfa

Modality: Small molecule (protein therapeutic)

Route of Administration: Subcutaneous injection

Formulations: 40 mg/ml and 100 mg/ml solutions for injection

Therapeutic Classification: Alimentary tract and metabolism (ATC A16)

Mechanism of Action: Not yet disclosed in available documentation

Target: Not yet disclosed in available documentation

Related Therapies: Asfotase alfa is the established standard of care for HPP; the Phase 3 trial directly compares ALXN1850 formulations against asfotase alfa, suggesting potential bioavailability, pharmacokinetic, or formulation optimization differences

First Approval: Japan (July 2015); United States (BLA125513); European Union (16 February 2026)

Patent Status: Not yet disclosed

European Union: Asfotase alfa (Strensiq) approved by the European Medicines Agency on 16 February 2026 (EMEA/H/C/003794) under Marketing Authorization Holder Alexion Europe SAS.

United States: Asfotase alfa approved under Biologics License Application (BLA) 125513 sponsored by Alexion Pharmaceuticals. Specific approval date not yet disclosed.

Japan: Asfotase alfa approved July 2015 by the Pharmaceuticals and Medical Devices Agency (PMDA).

China (NMPA): Regulatory status not yet disclosed.

Phase 3 Trial Status: ALXN1850-HPP-303 (Chestnut) is an active Phase 3 randomized, open-label, parallel-arm, active-controlled multicenter study in pediatric participants (2 to <12 years) with HPP previously treated with asfotase alfa. Expected next milestone and completion date not yet disclosed.

Strategic Positioning: Alexion's Phase 3 Chestnut trial represents a focused clinical development strategy targeting treatment-experienced pediatric HPP patients. The active-controlled design against asfotase alfa (rather than placebo) suggests the company is evaluating potential formulation, pharmacokinetic, or safety advantages within a defined population segment rather than establishing efficacy in a treatment-naive cohort. This approach may support label expansion, optimized dosing recommendations, or differentiation in pediatric practice.

Competitive Implications: With established approvals across major markets (Japan 2015, US date TBD, EU February 2026) and no disclosed competing HPP therapies in the rare disease space, Alexion maintains market dominance. The Phase 3 trial does not appear designed to defend against novel competitors but rather to strengthen the clinical evidence base and potentially expand market penetration within pediatric populations.

Regulatory and Commercial Catalysts: Phase 3 trial completion and data readout represent the primary near-term catalyst. Positive comparative efficacy or safety data could support pediatric label expansion, treatment optimization claims, or enhanced market positioning. The recent EU approval (February 2026) indicates active regulatory engagement and market expansion efforts.

Future Milestones: Expected next milestone timing and trial completion date not yet disclosed. Investors should monitor for Phase 3 data presentation, regulatory submissions for label expansion, and pediatric market uptake metrics in HPP treatment-experienced populations.